HIGH doses or long-term use of
proton pump inhibitors can lead to
a possible increased risk of
fractures, according to an alert
issued this week by the US Food
and Drug Administration.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 27 May 10 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 May 10
SIGMA Healthcare ceo Mark Hooper yesterday confirmed the company was “starting to see a return to growth in our brand member pipeline,” but said general trading conditions have continued to be challenging in the last quarter.